Compare SUNB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNB | IQV |
|---|---|---|
| Founded | 1947 | 1982 |
| Country | United States | United States |
| Employees | 8402 | 93000 |
| Industry | Diversified Commercial Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6B | 28.6B |
| IPO Year | 2026 | 2013 |
| Metric | SUNB | IQV |
|---|---|---|
| Price | $73.68 | $189.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $70.75 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 4.1M | 1.6M |
| Earning Date | 06-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $4.31 | $6.77 |
| Revenue Next Year | $5.06 | $5.89 |
| P/E Ratio | ★ N/A | $115.64 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $61.03 | $154.50 |
| 52 Week High | $86.68 | $247.05 |
| Indicator | SUNB | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 61.95 |
| Support Level | $71.96 | $159.91 |
| Resistance Level | $79.48 | $191.20 |
| Average True Range (ATR) | 2.98 | 6.50 |
| MACD | -1.24 | 0.61 |
| Stochastic Oscillator | 12.23 | 92.85 |
Sunbelt Rentals (formerly UK-based Ashtead Group) is the number two equipment rental company in the US (11% market share), with a smaller presence in Canada and the UK. Sunbelt operates a rental fleet of just over $15 billion across a network of 1,200 stores in the US, nearly CAD 2 billion of fleet and 135 stores in Canada, and GBP 1.1 billion and 190 stores in the UK. The company has experienced rapid growth over the past decade as its customers increasingly turn to rental versus owning equipment outright. The general tool business has been augmented by the Specialty Rental business, which has grown to 30% of the mix. Revenue is now greater than 50% nonconstruction, with the remainder focused more directly on commercial construction.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.